ArticleThe New England journal of medicine2012
HER2 therapy--an abundance of riches.
Article in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- ECD co-operates with ERBB2 to promote tumorigenesis through upregulation of unfolded protein response and glycolysis.Cancer letters · 2025Article
- HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.bioRxiv : the preprint server for biology · 2025Article
- Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review.Cancers · 2023Review
- Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors.Endocrine reviews · 2023Review
- Revisiting characteristics of oncogenic extrachromosomal DNA as mobile enhancers on neuroblastoma and glioma cancers.Cancer cell international · 2022Review
- Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine.Expert review of proteomics · 2021Review
- Review
- Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression.Journal of experimental & clinical cancer research : CR · 2020Review
- Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.Biomolecules · 2020Review
- Prevalence and role of HER2 mutations in cancer.Pharmacology & therapeutics · 2019Review
- Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.Frontiers in immunology · 2019Review
- Applications of RNA Indexes for Precision Oncology in Breast Cancer.Genomics, proteomics & bioinformatics · 2018Review
- Observational
- Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.Oncotarget · 2015Article
- Article
- Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Biochimica et biophysica acta · 2014Review
- Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.Journal of the National Cancer Institute · 2014Article
- Second malignancies after breast cancer: The impact of adjuvant therapy.Molecular and clinical oncology · 2014Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22149874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.